IONS
Ionis Pharmaceuticals, Inc. NASDAQ Listed May 17, 1991$74.12
-0.26%
vs $74.31
Mkt Cap $11.9B
52w Low $37.01
75.0% of range
52w High $86.50
50d MA $74.90
200d MA $75.00
P/E (TTM)
-31.1x
EV/EBITDA
—
P/B
24.2x
Debt/Equity
5.3x
ROE
-35.6%
P/FCF
-37.1x
RSI (14)
41.20
ATR (14)
$2.02
Beta
0.40
50d MA
$74.90
200d MA
$75.00
Avg Volume
1.7M
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
2855 Gazelle Court · Carlsbad, CA 92010 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | BMO | -0.85 | -0.56 | +34.1% | 71.78 | +0.4% | +4.2% | -0.1% | +0.7% | +0.2% | +1.4% | — |
| Feb 25, 2026 | BMO | -1.24 | -1.41 | -14.0% | 85.45 | -4.3% | -5.3% | -0.4% | +0.7% | +1.0% | -4.0% | — |
| Oct 29, 2025 | BMO | -1.15 | -0.61 | +47.0% | 73.57 | -1.6% | -2.3% | +3.2% | +0.2% | -0.9% | -1.0% | — |
| Jul 30, 2025 | BMO | 0.27 | 0.86 | +218.5% | 41.48 | +8.4% | +4.6% | -0.9% | +0.1% | +1.0% | -0.9% | — |
| Apr 30, 2025 | BMO | -1.11 | -0.75 | +32.4% | 29.81 | +6.6% | +3.0% | +3.3% | +3.4% | +2.7% | -5.3% | — |
| Feb 19, 2025 | BMO | -1.09 | -0.66 | +39.4% | 31.95 | +8.0% | -0.4% | +2.8% | -1.1% | -1.3% | -0.1% | — |
| Nov 6, 2024 | BMO | -1.16 | -0.95 | +18.1% | 38.80 | +3.0% | +0.6% | -1.5% | +1.9% | -0.8% | -2.9% | — |
| Aug 1, 2024 | BMO | -0.92 | -0.45 | +51.1% | 49.46 | +0.8% | +3.8% | -4.3% | -4.3% | +0.1% | -0.5% | — |
| May 7, 2024 | BMO | -1.05 | -0.98 | +6.4% | 42.28 | -3.1% | -3.2% | -1.9% | -1.7% | -1.0% | -0.7% | — |
| Feb 21, 2024 | BMO | -0.83 | -0.06 | +92.8% | 44.35 | +3.5% | -1.8% | +1.0% | +3.1% | +1.6% | +2.8% | — |
| Nov 2, 2023 | BMO | -1.04 | -1.03 | +1.0% | 45.26 | +1.7% | -3.4% | +7.9% | -1.9% | +3.1% | -1.3% | — |
| Aug 9, 2023 | BMO | -0.90 | -0.60 | +33.3% | 39.55 | +4.0% | +1.1% | -0.4% | +1.0% | -0.8% | +0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 19 | Citigroup | Initiates | Buy | $115 | $72.52 | $72.76 | +0.3% | +1.8% | +1.7% | +1.0% | -0.3% | +0.7% |
| Apr 30 | Barclays | Maintains | Overweight → Overweight | — | $74.83 | $74.91 | +0.1% | -0.1% | +0.7% | +0.2% | -0.3% | +2.1% |
| Apr 30 | RBC Capital | Maintains | Outperform → Outperform | — | $74.83 | $74.91 | +0.1% | -0.1% | +0.7% | +0.2% | -0.3% | +2.1% |
| Apr 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $74.83 | $74.91 | +0.1% | -0.1% | +0.7% | +0.2% | -0.3% | +2.1% |
| Apr 23 | TD Cowen | Maintains | Buy → Buy | — | $74.83 | $74.96 | +0.2% | -1.0% | -1.1% | -1.4% | -0.6% | +4.2% |
| Apr 21 | Canaccord Genuity | Initiates | Buy | $110 | $74.87 | $75.87 | +1.3% | -0.1% | +0.1% | -1.0% | -1.1% | -1.4% |
| Apr 21 | Morgan Stanley | Maintains | Overweight → Overweight | — | $74.87 | $75.87 | +1.3% | -0.1% | +0.1% | -1.0% | -1.1% | -1.4% |
| Apr 9 | BofA Securities | Maintains | Buy → Buy | — | $74.98 | $74.98 | +0.0% | +1.9% | -1.6% | -0.3% | +2.4% | +0.1% |
| Mar 26 | Barclays | Maintains | Overweight → Overweight | — | $72.70 | $72.25 | -0.6% | +2.1% | -2.8% | +0.5% | +3.5% | +0.1% |
| Mar 25 | Needham | Maintains | Buy → Buy | — | $69.68 | $70.68 | +1.4% | +4.3% | +2.1% | -2.8% | +0.5% | +3.5% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $69.68 | $70.68 | +1.4% | +4.3% | +2.1% | -2.8% | +0.5% | +3.5% |
| Mar 3 | Leerink Partners | Maintains | Outperform → Outperform | — | $81.96 | $80.42 | -1.9% | -4.0% | +1.0% | -5.4% | -1.5% | +1.8% |
| Feb 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $80.60 | $80.59 | -0.0% | +0.7% | +1.0% | -4.0% | +1.0% | -5.4% |
| Feb 26 | Stifel | Maintains | Hold → Hold | — | $80.93 | $80.32 | -0.8% | -0.4% | +0.7% | +1.0% | -4.0% | +1.0% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $80.93 | $80.32 | -0.8% | -0.4% | +0.7% | +1.0% | -4.0% | +1.0% |
| Feb 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $83.48 | $84.85 | +1.6% | +3.6% | -2.0% | -0.6% | +0.1% | -3.0% |
| Jan 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $79.67 | $79.18 | -0.6% | -1.4% | +3.8% | +2.1% | -2.0% | -1.5% |
| Dec 17 | RBC Capital | Maintains | Outperform → Outperform | — | $78.37 | $78.77 | +0.5% | -1.6% | +0.7% | +2.5% | +2.2% | -1.2% |
| Dec 15 | Leerink Partners | Maintains | Outperform → Outperform | — | $80.82 | $80.35 | -0.6% | -1.3% | -1.7% | -1.6% | +0.7% | +2.5% |
| Dec 9 | BofA Securities | Maintains | Buy → Buy | — | $81.51 | $80.55 | -1.2% | -3.3% | -0.3% | +0.6% | +2.1% | -1.3% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $73.55 | $70.05 | -4.8% | -5.5% | +4.2% | +0.3% | -3.9% | +2.4% |
| Nov 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $73.65 | $72.40 | -1.7% | -1.0% | +2.5% | -0.8% | -0.7% | -5.5% |
| Oct 30 | Barclays | Maintains | Overweight → Overweight | — | $71.88 | $71.91 | +0.0% | +3.2% | +0.2% | -0.9% | -1.0% | +2.5% |
| Oct 30 | Needham | Maintains | Buy → Buy | — | $71.88 | $71.91 | +0.0% | +3.2% | +0.2% | -0.9% | -1.0% | +2.5% |
| Oct 30 | TD Cowen | Maintains | Buy → Buy | — | $71.88 | $71.91 | +0.0% | +3.2% | +0.2% | -0.9% | -1.0% | +2.5% |
| Oct 30 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $71.88 | $71.91 | +0.0% | +3.2% | +0.2% | -0.9% | -1.0% | +2.5% |
| Oct 30 | Morgan Stanley | Maintains | Overweight → Overweight | — | $71.88 | $71.91 | +0.0% | +3.2% | +0.2% | -0.9% | -1.0% | +2.5% |
| Oct 30 | RBC Capital | Maintains | Outperform → Outperform | — | $71.88 | $71.91 | +0.0% | +3.2% | +0.2% | -0.9% | -1.0% | +2.5% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $71.88 | $71.91 | +0.0% | +3.2% | +0.2% | -0.9% | -1.0% | +2.5% |
| Oct 16 | Morgan Stanley | Maintains | Overweight → Overweight | — | $72.39 | $73.12 | +1.0% | +0.9% | +0.0% | +0.6% | -2.6% | -0.2% |
| Oct 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $68.94 | $70.49 | +2.2% | +1.5% | +0.4% | -0.4% | +0.9% | +1.1% |
| Oct 8 | Needham | Maintains | Buy → Buy | — | $68.94 | $70.49 | +2.2% | +1.5% | +0.4% | -0.4% | +0.9% | +1.1% |
| Oct 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $68.94 | $70.49 | +2.2% | +1.5% | +0.4% | -0.4% | +0.9% | +1.1% |
| Oct 8 | JP Morgan | Upgrade | Neutral → Overweight | — | $68.94 | $70.49 | +2.2% | +1.5% | +0.4% | -0.4% | +0.9% | +1.1% |
| Oct 6 | Stifel | Maintains | Hold → Hold | — | $69.15 | $69.15 | +0.0% | -0.2% | -0.1% | +1.5% | +0.4% | -0.4% |
| Sep 26 | Goldman Sachs | Upgrade | Sell → Neutral | — | $62.97 | $64.03 | +1.7% | +1.8% | +0.1% | +2.0% | +0.6% | +4.0% |
| Sep 23 | Guggenheim | Maintains | Buy → Buy | — | $61.36 | $61.51 | +0.2% | +2.0% | +2.2% | -1.5% | +1.8% | +0.1% |
| Sep 23 | Barclays | Maintains | Overweight → Overweight | — | $61.36 | $61.51 | +0.2% | +2.0% | +2.2% | -1.5% | +1.8% | +0.1% |
| Sep 23 | BofA Securities | Maintains | Buy → Buy | — | $61.36 | $61.51 | +0.2% | +2.0% | +2.2% | -1.5% | +1.8% | +0.1% |
| Sep 23 | Morgan Stanley | Maintains | Overweight → Overweight | — | $61.36 | $61.51 | +0.2% | +2.0% | +2.2% | -1.5% | +1.8% | +0.1% |
| Sep 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $61.36 | $61.51 | +0.2% | +2.0% | +2.2% | -1.5% | +1.8% | +0.1% |
| Sep 4 | RBC Capital | Maintains | Outperform → Outperform | — | $60.49 | $59.34 | -1.9% | -1.9% | +3.2% | -0.4% | +5.6% | -0.6% |
| Sep 3 | Barclays | Maintains | Overweight → Overweight | — | $57.49 | $58.98 | +2.6% | +5.2% | -1.9% | +3.2% | -0.4% | +5.6% |
| Sep 3 | BMO Capital | Upgrade | Market Perform → Outperform | — | $57.49 | $58.98 | +2.6% | +5.2% | -1.9% | +3.2% | -0.4% | +5.6% |
| Sep 3 | Goldman Sachs | Maintains | Sell → Sell | — | $57.49 | $58.98 | +2.6% | +5.2% | -1.9% | +3.2% | -0.4% | +5.6% |
| Sep 3 | Citigroup | Maintains | Buy → Buy | — | $57.49 | $58.98 | +2.6% | +5.2% | -1.9% | +3.2% | -0.4% | +5.6% |
| Sep 2 | Jefferies | Maintains | Buy → Buy | — | $42.64 | $49.14 | +15.2% | +34.8% | +5.2% | -1.9% | +3.2% | -0.4% |
| Sep 2 | Needham | Maintains | Buy → Buy | — | $42.64 | $49.14 | +15.2% | +34.8% | +5.2% | -1.9% | +3.2% | -0.4% |
| Sep 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.64 | $49.14 | +15.2% | +34.8% | +5.2% | -1.9% | +3.2% | -0.4% |
| Aug 25 | Needham | Maintains | Buy → Buy | — | $42.69 | $42.82 | +0.3% | -2.0% | +0.8% | +1.4% | -0.3% | +0.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | BERTHELSEN SPENCER RDir | — | Sell | 8,000 | $73.49 | $588K | 156,013 | +1.67% | — |
| Jun 12, 2026 | Kordasiewicz Holly B.Off | EVP, Chief Development Officer | Sell | 19,842 | $74.05 | $1.5M | 22,458 | +1.67% | — |
| Jun 12, 2026 | Kordasiewicz Holly B.Off | EVP, Chief Development Officer | Sell | 41,004 | $73.09 | $3.0M | 42,300 | +1.67% | — |
| Jun 1, 2026 | BERTHELSEN SPENCER RDir | — | Sell | 8,000 | $75.67 | $605K | 156,013 | +1.77% | -1.69% |
| May 4, 2026 | LOSCALZO JOSEPHDir | — | Sell | 17,781 | $75.58 | $1.3M | 36,330 | -1.08% | +2.33% |
| May 4, 2026 | LOSCALZO JOSEPHDir | — | Sell | 59,508 | $74.90 | $4.5M | 54,111 | -1.08% | +2.33% |
| May 1, 2026 | KLEIN JOSEPH IIIDir | — | Sell | 1,431 | $74.45 | $107K | 11,014 | +2.13% | +0.60% |
| May 1, 2026 | KLEIN JOSEPH IIIDir | — | Sell | 8,680 | $73.35 | $637K | 12,445 | +2.13% | +0.60% |
| Apr 28, 2026 | Baroldi JosephOff | EVP, Chief Business Officer | Sell | 1,626 | $71.79 | $117K | 44,909 | +0.70% | -1.08% |
8-K · 8.01
!! High
Ionis Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 12
8-K · 5.02
!!! Very High
Ionis Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Jun 8
8-K · 8.01
!! High
Ionis Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Ionis gains validation for its partnership with GSK as bepirovirsen achieves positive Phase 3 data for chronic hepatitis B, potentially advancing the ASO toward regulatory approval and commercial viability.
May 28
8-K
Ionis Pharmaceuticals, Inc. -- 8-K Filing
Ionis Pharmaceuticals issued a press release on April 29, 2026, but the specific business development or financial impact cannot be determined from this limited filing summary.
Apr 29
8-K · 8.01
!! High
Ionis Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Ionis Pharmaceuticals reported positive pivotal study results for zilganersen treating AxD, a rare neurological disease, strengthening prospects for regulatory approval and potential market entry in an underserved patient population.
Apr 21
8-K · 5.02
!!! Very High
Ionis Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
B. Lynne Parshall departed Ionis Pharmaceuticals' board on March 3, 2026, reducing board oversight capacity and potentially signaling internal governance shifts that investors should monitor.
Mar 9
8-K
Ionis Pharmaceuticals, Inc. -- 8-K Filing
I cannot provide a meaningful analysis based on this summary, as it lacks substantive deal or business information—it only references a press release date without disclosing actual news content or financial terms.
Feb 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 24,556,637 | $1.8B | Added | Mar 2026 |
| 2 | Capital World Investors | 21,186,369 | $1.6B | Added | Mar 2026 |
| 3 | Vanguard Portfolio Management Llc | 7,808,902 | $586M | New | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 7,118,330 | $535M | New | Mar 2026 |
| 5 | Two Sigma Investments, Lp | 5,857,629 | $440M | Added | Mar 2026 |
| 6 | Royal Bank Of Canada | 3,801,815 | $285M | Added | Mar 2026 |
| 7 | Jpmorgan Chase & Co | 2,363,567 | $171M | Added | Mar 2026 |
| 8 | Morgan Stanley | 2,039,812 | $161M | Reduced | Dec 2025 |
| 9 | Artisan Partners Limited Partnership | 2,058,308 | $155M | Added | Mar 2026 |
| 10 | Deerfield Management Company, L.p. | 1,979,669 | $149M | — | Mar 2026 |
| 11 | Bellevue Group Ag | 1,818,665 | $137M | Reduced | Mar 2026 |
| 12 | Franklin Resources Inc | 1,575,023 | $118M | Added | Mar 2026 |
| 13 | Pictet Asset Management Holding Sa | 1,418,491 | $112M | Added | Dec 2025 |
| 14 | Invesco Ltd. | 1,277,358 | $96M | Added | Mar 2026 |
| 15 | Connor, Clark & Lunn Investment Management Ltd. | 1,076,370 | $85M | Added | Dec 2025 |
| 16 | Millennium Management | 1,051,506 | $79M | Added | Mar 2026 |
| 17 | Citadel Advisors Llc | 942,534 | $71M | Reduced | Mar 2026 |
| 18 | Bnp Paribas Asset Management Holding S.a. | 907,533 | $68M | Reduced | Mar 2026 |
| 19 | Northern Trust Corp | 868,179 | $65M | Added | Mar 2026 |
| 20 | Bank Of America Corp /de/ | 840,598 | $63M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$11.86B
Enterprise Value
$11.08B
P/E (TTM)
-31.14x
Forward P/E
—
PEG Ratio
1.53x
P/B
24.25x
P/S
12.56x
P/FCF
-37.06x
EV/EBITDA
—
Shares Out
160.0M
Financials (TTM)
Revenue
$944.0M
Net Income
-$381.0M
EBITDA
-$286.7M
Free Cash Flow
-$320.0M
Op Cash Flow
-$268.6M
EPS Basic
$-2.38
EPS Diluted
$-2.38
EPS Forward
$-3.83
Gross Margin
98.3%
Op Margin
-40.5%
Net Margin
-40.4%
Balance Sheet
Total Assets
$3.52B
Total Liab.
$3.03B
Total Equity
$489.1M
Cash
$2.68B
LT Debt
$1.90B
Book Value/Sh
$3.06
Debt/Equity
5.35x
Current Ratio
3.83
Quick Ratio
3.81
Returns & Growth
ROE
-35.6%
ROA
-5.1%
ROIC
-12.0%
Rev Growth YoY
+33.9%
EPS Growth YoY
+21.7%
Price Returns
2W
+1.1%
1M
+2.3%
3M
-5.7%
6M
-7.5%
12M
+128.3%
Technicals
52W High
$86.50
52W Low
$37.01
50d MA
$74.90
200d MA
$75.00
RSI (14)
41.20
ATR (14)
$2.02
Beta
0.40
Avg Volume
1.7M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$107.27
High
$130.00
Low
$87.00
Median
$104.00
Data updated apr 25, 2026 3:58pm
· Source: financialmodelingprep.com